| CAS NO: | 21802-37-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Molecular Weight (MW) | 229.23 |
|---|---|
| Formula | C12H11N3O2 |
| CAS No. | 21802-37-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 150 mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| Chemical Name | (E)-4-methoxy-[2,2'-bipyridine]-6-carbaldehyde oxime |
| Synonyms | NSC-114341; NSC114341; NSC 114341; Carulomycin A; AC1NTHG8; AC1N-THG8; AC1N THG8; HE185727; HE 185727; HE-185727 |
| SMILES Code | COC1=CC(C2=NC=CC=C2)=NC(/C=N/O)=C1 |
Purity ≥98%
COA
MSDS
CaeA alone and in conjunction with TGF-β augments the pool of Tregs. J Biol Chem. 2014 Jun 20;289(25):17515-28. |
CaeA ameliorated the symptoms of experimental arthritis by generating Tregs. Arthritis-induced mice were treated with CaeA. A, disease progression. J Biol Chem. 2014 Jun 20;289(25):17515-28. |
CaeA antagonized the IFN-γ- and IL-6-mediated STAT1 signaling pathway in CD4 T cells by enhancing SOCS1 expression. J Biol Chem. 2014 Jun 20;289(25):17515-28. |
m.cnreagent.com
